title: Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
abstract: In 23 evaluable patients with advanced ovarian epithelial cancer refractory to combination therapy with cisplatin and an alkylating agent, teniposide (VM-26) was administered as a short-term i.v. infusion at a dose of 100 mg/m2 on days 1 and 2, every 3 weeks. Toxicity was moderate and comparable to the pattern known from other studies. No objective response has been observed, showing that teniposide is not active as second-line therapy in this disease.
authors: Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
authors: M E
authors: ME
authors: van der Burg
authors: W W
authors: WW
authors: ten Bokkel Huinink
authors: R
authors: R
authors: Vriesendorp
authors: A T
authors: AT
authors: van Oosterom
authors: J P
authors: JP
authors: Neijt
authors: J B
authors: JB
authors: Vermorken
authors: W L
authors: WL
authors: van Putten
authors: A
authors: A
authors: Kooiman
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011379:Prognosis; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D013713:Teniposide; D011034:Podophyllotoxin